Analyses of emerging macrocyclic lactone resistance: Speed and signature of ivermectin and moxidectin selection and evidence of a shared genetic locus. [PDF]
PLoS PathogensSubtherapeutic treatment or 'underdosing' is considered a common problem in the control of parasitic helminths of animals and people and can hasten the emergence of anthelmintic resistance.
Jennifer McIntyre +8 more
doaj +3 more sources
Moxidectin is a candidate for use as an in vivo internal standard in pharmacokinetic studies, as demonstrated with use in simultaneous tissue cage and ultrafiltration fluid collection [PDF]
Frontiers in Veterinary ScienceIn vivo ultrafiltration has been used in veterinary pharmacokinetics since the early 2000’s as an improvement on the tissue cage model which enables sampling of fluids from extra-circulatory compartments.
Richard Munn +3 more
doaj +3 more sources
Exposure of gut bacterial isolates to the anthelminthic drugs, ivermectin and moxidectin, leads to antibiotic-like phenotypes of growth inhibition and adaptation [PDF]
Communications BiologyDue to their broad-spectrum activities, ivermectin and moxidectin are widely used anthelminthics in veterinary and human medicine. However, ivermectin has recently been shown to perturbate bacterial growth.
Julian Dommann +8 more
doaj +3 more sources
Moxidectin: an oral treatment for human onchocerciasis [PDF]
Expert Review of Anti-Infective Therapy, 2020 Introduction Moxidectin is a milbemycin endectocide recently approved for the treatment of human onchocerciasis. Onchocerciasis, earmarked for elimination of transmission, is a filarial infection endemic in Africa, Yemen, and the Amazonian focus ...
Philip Milton +2 more
exaly +6 more sources
The use of quantitative clinical pharmacology approaches to support moxidectin dosing recommendations in lactation. [PDF]
PLoS Neglected Tropical DiseasesMoxidectin is approved by the US Food and Drug Administration (US FDA) for the treatment of onchocerciasis (river-blindness) due to Onchocerca volvulus in patients aged 12 years and older.
Nolan D Wood +7 more
doaj +3 more sources
PLoS ONE, 2022 Formulations of macrocyclic lactone anthelmintics such as moxidectin are regularly administered to sheep to combat parasites. A disadvantage of these pharmaceuticals are their side effects on non-target organisms when entering the environment.
Carsten Eichberg +4 more
doaj +5 more sources
Treatment of Sarcoptic Mange in Wombats With Topical Moxidectin. [PDF]
Vet Med SciSarcoptic mange is a debilitating disease affecting free‐living/wild bare‐nosed wombats (Vombatus ursinus). The disease causes thickening of the skin, pruritus, alopecia and deep fissures in the skin of infected animals, and ultimately death if left ...
Stannard HJ +5 more
europepmc +5 more sources
Bugs and drugs: a systems biology approach to characterising the effect of moxidectin on the horse’s faecal microbiome [PDF]
Animal Microbiome, 2020 Background Anthelmintic treatment is a risk factor for intestinal disease in the horse, known as colic. However the mechanisms involved in the onset of disease post anthelmintic treatment are unknown.
S. P. Daniels +3 more
doaj +2 more sources
Pharmacokinetics of oral moxidectin in individuals with Onchocerca volvulus infection.
PLoS Neglected Tropical Diseases, 2022 BackgroundOnchocerciasis ("river blindness"), is a neglected tropical disease caused by the filarial nematode Onchocerca volvulus and transmitted to humans through repeated bites by infective blackflies of the genus Simulium.
Beesan Tan +9 more
doaj +2 more sources
Field efficacy and safety evaluation of a novel chewable tablet (Credelio Quattro™) containing lotilaner, moxidectin, praziquantel, and pyrantel against gastrointestinal nematode infections in dogs in the USA. [PDF]
Parasit VectorsGastrointestinal nematodes such as hookworms (Ancylostoma caninum) and roundworms (Toxocara canis) commonly infect dogs and are zoonotic parasites capable of producing clinical disease in humans.
Charles S +4 more
europepmc +2 more sources